Intralesional verapamil prevents the progression of Peyronie's disease Journal Article
| Authors: | Bennett, N. E.; Guhring, P.; Mulhall, J. P. |
| Article Title: | Intralesional verapamil prevents the progression of Peyronie's disease |
| Abstract: | Objectives: To define the impact of intralesional verapamil injection therapy on penile deformity in men with Peyronie's disease. Methods: Patients underwent a total of 6 intralesional injections of verapamil. Penile deformity was assessed at baseline and 3 months after the last intralesional injection of verapamil during penile erection after the administration of intracavernosal medication. Measurement was recorded using a goniometer at maximum penile rigidity. Endpoints included change in magnitude of curvature, stretched penile length, penetration ability, and resolution of pain. Results: Ninety-four consecutive patients met all inclusion criteria. Mean (± standard deviation) patient age and duration of Peyronie's disease at time of baseline deformity assessment were 44 ± 18 years and 5.2 ± 2.7 months, respectively. At baseline 86% had dorsal and 14% lateral curvature. The mean curvature and stretched flaccid length were 50° ± 28° and 12.6 ± 3.1 cm, respectively. At the follow-up evaluation, patients were 5.2 ± 1.8 months after their last ILV injection and were 11.7 ± 4.2 months after the onset of Peyronie's disease. Eighteen percent of patients had improvement of curvature, 60% were unchanged, and 22% worsened. Pain resolved in 100% of patients. Conclusions: In response to intralesional verapamil, a minority of men experienced improvement in penile deformity; however, the majority of patients had stabilization of their deformity. This information may permit clinicians to give realistic expectations to patients considering intralesional verapamil therapy. © 2007 Elsevier Inc. All rights reserved. |
| Keywords: | adult; controlled study; treatment outcome; middle aged; major clinical study; clinical trial; drug efficacy; follow-up studies; controlled clinical trial; pain; morphology; time factors; disease progression; verapamil; vasodilator agents; peyronie disease; penile induration; ecchymosis; injections, intralesional; deformity; male genital system function |
| Journal Title: | Urology |
| Volume: | 69 |
| Issue: | 6 |
| ISSN: | 0090-4295 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2007-06-01 |
| Start Page: | 1181 |
| End Page: | 1184 |
| Language: | English |
| DOI: | 10.1016/j.urology.2007.02.042 |
| PUBMED: | 17572211 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 20" - "Export Date: 17 November 2011" - "CODEN: URGYA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work